What happened with OGN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Most of Organon’s revenue comes from its Established Brands portfolio, largely sold outside the United States. Most of these medicines have lost market exclusivity and compete with generics. Drug wholesalers, pharmacies, hospitals and other healthcare institutions buy its products for use by patients; most company-wide sales also come from outside the United States.
Women’s health is its next-largest business, mainly prescription contraception and fertility treatments, including the Nexplanon contraceptive implant. Organon also sells medicines that closely match existing biological drugs, known as biosimilars. That smaller business relies primarily on products developed and manufactured by Samsung Bioepis, which Organon sells under commercialization agreements with geographic limits.
Sales depend on continued access to healthcare funding and insurance coverage, as governments and private payors influence prices and reimbursement. Supply also depends on outside manufacturers and sole-source inputs; Organon relies heavily on one formulation or packaging supplier that enables sales in Japan and China. It must obtain and maintain regulatory authorization in each market. In the United States, Nexplanon’s five-year use indication requires healthcare providers to complete training and enroll in an FDA-mandated safety program.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Organon’s results hinge chiefly on erosion in international mature brands and contraceptive demand, with Samsung Bioepis an important partner behind its biosimilars.
Teva sells generic medicines and biosimilars that compete with Organon’s mostly off-patent established brands and its biosimilars. Watch Teva’s generic launches in overseas markets, where Organon earned 91% of its established-brand revenue in 2025.
Organon relies on Merck’s licensed technology for Nexplanon, its largest women’s health product, while Merck also pays Organon to manufacture and package medicines. The technology tie underpins Nexplanon/Implanon NXT sales, which totaled $921 million in 2025.
AbbVie’s Humira competes with Organon’s Hadlima, a biologic medicine sold as a similar alternative, so AbbVie’s immunology pricing and contract terms matter directly to Hadlima’s growth. Hadlima sales rose from $142 million in 2024 to $228 million in 2025, making it a concrete revenue line to watch.
Pfizer competes for Organon’s contraceptive and biosimilar sales through injectable contraception and biosimilar alternatives to Organon’s infliximab and trastuzumab products.
Organon depends on Lilly to supply Emgality, which Organon sells under a distribution agreement in Europe, Canada and other specified markets. Lilly’s Emgality supply news therefore matters to the product revenue Organon earns in those markets.
Eli Lilly & Co. earningsLLY
Lilly’s report may show whether Emgality supply is steady for Organon’s sales in Europe, Canada and other specified markets.
Look for explicit Lilly comments on Emgality production, supply or disruption; Lilly’s overall sales are not Organon’s sales. Steady supply would mean no new supply obstacle for Organon’s distribution of Emgality in these markets. A disclosed interruption could limit product available to sell and put Organon’s related revenue at risk.
Merck & Co., Inc. earningsMRK
Merck’s report may reveal changes to the licensed technology or related supply behind Organon’s largest women’s health product, Nexplanon.
Look for an explicit Merck disclosure about the licensed technology or related supply for Nexplanon; Merck’s overall results do not substitute for Organon’s product figures. No such change disclosed would leave the technology link behind Organon’s $921 million in 2025 Nexplanon/Implanon NXT sales without a new warning. A disclosed impact on the license or supply could put this important revenue stream and product availability at risk.
ABBVIE INC. earningsABBV
AbbVie’s report may show how Humira’s pricing and contract terms are changing, indicating the competitive pressure Organon’s Hadlima faces in winning customers.
Compare AbbVie’s comments on Humira demand, pricing and contract terms with Hadlima sales, which rose from $142 million in 2024 to $228 million in 2025. Weaker Humira competitiveness alongside continued Hadlima growth would suggest Hadlima is still winning customers. More attractive Humira pricing or terms alongside slower Hadlima growth would point to tougher customer competition and less room for Hadlima to expand.
Teva Pharmaceutical Industries Limited earningsTEVA
Teva’s report may show whether generic launches or sales overseas are intensifying competition for Organon’s established brands.
Look for Teva disclosures on overseas generic launches and sales, against the fact that about 91% of Organon’s established-brand revenue came from outside the U.S. in 2025; Teva’s overall results are not Organon’s results. More launches or stronger generic competition would make it harder for Organon’s off-patent brands to defend price and volume. Easing competition would mean less pressure on this overseas revenue stream.
Organon & Co. earningsThis company
Organon’s report will show whether sales and gross profit across its women’s health, biosimilars and established brands can support cash generation and debt repayment.
Read sales across the product groups alongside gross margin, the share of sales left after product costs. Steadier sales and a margin that stops shrinking would show product revenue is absorbing competitive and cost pressures, supporting cash for debt repayment. Falling sales and a thinner margin would show cash generation remains squeezed and leave less room to reduce debt.
